Frenzel, Martin

MONARCH 3: Abemaciclib As Initial Therapy for Advanced Breast Cancer

Goetz, M. P., Toi, M., Campone, M., Sohn, J., Paluch-Shimon, S., Huober, J., Park, I. H., Trédan, O., Chen, S.-C., Manso, L., et al. (2017) · Journal of Clinical Oncology

Advanced Breast Cancer TherapiesBreast Cancer Treatment Studies

Cited by 1,744

MONARCH 2: abemaciclib in combination with fulvestrant in women with HR+/HER2- advanced breast cancer who had progressed while receiving endocrine therapy

Sledge, G. W., Toi, M., Neven, P., Sohn, J., Inoue, K., Pivot, X., Burdaeva, O., Okera, M., Masuda, N., Kaufman, P. A., et al. (2017) · Journal of Clinical Oncology

Advanced Breast Cancer TherapiesBreast Cancer Treatment Studies

Cited by 1,680

The Effect of Abemaciclib Plus Fulvestrant on Overall Survival in Hormone Receptor–Positive, ERBB2-Negative Breast Cancer That Progressed on Endocrine Therapy—MONARCH 2: A Randomized Clinical Trial

Sledge, G. W., Toi, M., Neven, P., Sohn, J., Inoue, K., Pivot, X., Burdaeva, O., Okera, M., Masuda, N., Kaufman, P. A., et al. (2020) · JAMA Oncology

Advanced Breast Cancer TherapiesBreast Cancer Treatment Studies

Cited by 991

Efficacy and Safety of Abemaciclib, an Inhibitor of CDK4 and CDK6, for Patients with Breast Cancer, Non–Small Cell Lung Cancer, and Other Solid Tumors

Patnaik, A., Rosen, L. S., Tolaney, S. M., Tolcher, A. W., Goldman, J. W., Gandhi, L., Papadopoulos, K. P., Beeram, M., Rasco, D. W., Hilton, J. F., et al. (2016) · Cancer Discovery

Advanced Breast Cancer TherapiesPI3K/AKT/mTOR signaling in cancer

Cited by 743

MONARCH 3 final PFS: a randomized study of abemaciclib as initial therapy for advanced breast cancer

Johnston, S., Martin, M., Di Leo, A., Im, S.-A., Awada, A., Forrester, T., Frenzel, M., Hardebeck, M. C., Cox, J., Barriga, S., et al. (2019) · npj Breast Cancer

Advanced Breast Cancer TherapiesBreast Cancer Treatment Studies

Cited by 685

Prognostic characteristics in hormone receptor-positive advanced breast cancer and characterization of abemaciclib efficacy

Di Leo, A., O’Shaughnessy, J., Sledge, G. W., Martin, M., Lin, Y., Frenzel, M., Hardebeck, M. C., Smith, I. C., Llombart-Cussac, A., Goetz, M. P., et al. (2018) · npj Breast Cancer

Advanced Breast Cancer TherapiesBreast Cancer Treatment Studies

Cited by 66

Abstract CT232: clinical activity of LY2835219, a novel cell cycle inhibitor selective for CDK4 and CDK6, in patients with metastatic breast cancer

Patnaik, A., Rosen, L. S., Tolaney, S. M., Tolcher, A. W., Goldman, J. W., Gandhi, L., Papadopoulos, K. P., Beeram, M., Rasco, D. W., Myrand, S. P., et al. (2014) · Cancer Research

Advanced Breast Cancer TherapiesBreast Cancer Treatment Studies

Cited by 44

LY2835219, a novel cell cycle inhibitor selective for CDK4/6, in combination with fulvestrant for patients with hormone receptor positive (HR+) metastatic breast cancer

Patnaik, A., Rosen, L. S., Tolaney, S. M., Tolcher, A. W., Goldman, J. W., Gandhi, L., Papadopoulos, K. P., Beeram, M., Rasco, D. W., Myrand, S. P., et al. (2014) · Journal of Clinical Oncology

Advanced Breast Cancer TherapiesBreast Cancer Treatment Studies

Cited by 42

Clinical activity of LY2835219, a novel cell cycle inhibitor selective for CDK4 and CDK6, in patients with non-small cell lung cancer

Goldman, J. W., Gandhi, L., Patnaik, A., Rosen, L. S., Hilton, J. F., Papadopoulos, K. P., Tolaney, S. M., Beeram, M., Rasco, D. W., Myrand, S. P., et al. (2014) · Journal of Clinical Oncology

Lung Cancer Treatments and MutationsAdvanced Breast Cancer Therapies

Cited by 27

Abstract P5-19-13: clinical activity of abemaciclib, an oral cell cycle inhibitor, in metastatic breast cancer

Tolaney, S. M., Rosen, L. S., Beeram, M., Goldman, J. W., Gandhi, L., Tolcher, A. W., Papadopoulos, K. P., Rasco, D. W., Myrand, S. P., Kulanthaivel, P., et al. (2015) · Cancer Research

Advanced Breast Cancer TherapiesBreast Cancer Treatment Studies

Cited by 13